WHO MOC
There was a significant treatment benefit for patients receiving
nebulised UFH on top of standard of care versus patients treated with
standard of care only as assessed by the WHO MOCS (Table 7). At day 29,
the treatment difference reached significance in all analysis
populations (p<0.1).
Table 6 – Evolution of the MOOC WHO scale following treatment with
standard of care or heparin plus standard of care